TABLE 2

Metabolic parameters from IVGTTs at baseline and 3 months on trial

Placebo group (n = 109)
Troglitazone group (n = 108)
Baseline3 monthsPBaseline3 monthsP
Fasting glucose (mg/dl)94.3 ± 10.497.2 ± 14.50.00994.5 ± 10.091.0 ± 10.4<0.0001
Kg (min−1 × 100)1.49 ± 0.401.48 ± 0.410.991.43 ± 0.411.46 ± 0.480.53
SI (min−1 per μU/ml × 10−4)2.34 ± 1.802.17 ± 1.480.172.60 ± 1.673.76 ± 2.27<0.0001
Insulin area (μU/ml × min)10518 ± 5,54410701 ± 5,6730.909,402 ± 5,5046,551 ± 3,644<0.0001
AIRg (μU/ml × min)542 ± 499534 ± 4600.91461 ± 357406 ± 2940.10
DI995 ± 709969 ± 7200.35987 ± 7201321 ± 852<0.0001
  • Data are means ± SD from all women who had IVGTTs at both times. P values are for difference from zero of change in each group between baseline and 3 months, by Wilcoxon’s signed-rank test.